Organon Dermatology to present new Phase 3 analysis of VTAMA eczema data at the Society for Pediatric Dermatology annual meeting on July 23, 2026.
The country’s largest lender, State Bank of India (SBI), and 10 other global banks, have combined forces to finance one of ...
Zacks Investment Research on MSN
Investors heavily search Organon & Co. (OGN): Here is what you need to know
Organon (OGN) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the past ...
We recently compiled a list of the 12 Best Low-Priced Pharma Stocks to Buy Right Now. Organon & Co. (NYSE:OGN) is one of the ...
India's dealmaking landscape in the April-June quarter was dominated by a handful of blockbuster transactions, with Sun ...
Five years after launching as a global healthcare company committed to delivering impactful medicines and solutions for a ...
After picking up European rights to a pair of Eli Lilly migraine meds in December, Organon, the women’s health-focused spinoff of Merck & Co., is hungry to ink more deals. “It’s not a one-off,” ...
The company has submitted a Form DEFM14A to the SEC, indicating an upcoming shareholder vote. This form gives shareholders all the information they need to develop an informed vote. Read on to learn ...
JERSEY CITY, N.J. & SAN FRANCISCO--(BUSINESS WIRE)--Organon (NYSE:OGN) and Sempre Health today announced a strategic partnership designed to motivate eligible patients to refill their prescriptions on ...
After a tumultuous run on its own as a public company following its 2021 spinoff from Merck, Organon appears likely to be acquired by Sun Pharmaceutical Industries for $14 per share in cash. The ...
Add Yahoo as a preferred source to see more of our stories on Google. (Reuters) -Women health-focused company Organon said on Wednesday it has agreed to buy Roivant's unit Dermavant for up to $1.2 ...
Sun Pharma expects strong cash flows from the combined business to support debt reduction, innovation investments and growth across specialty medicines, women’s health and global markets.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results